Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by LianBio
LianBio Announces Voluntarily Delisting from Nasdaq
February 28, 2024
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Completion of Strategic Review
February 13, 2024
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
December 26, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Departure of Chief Financial Officer
December 20, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Departure of Chief Executive Officer
December 19, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
December 06, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
December 01, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
October 30, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023
October 25, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
October 24, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology
August 28, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
August 03, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis
July 26, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand
July 18, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023
July 17, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
July 12, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
June 26, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
June 08, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China
June 06, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio to Participate in Upcoming Investor Conferences
June 01, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China
May 11, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
April 26, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Promotes Pascal Qian to Chief Commercial Officer
April 21, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
April 21, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 27, 2023
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Announces President and Chief Strategy Officer Departure
December 13, 2022
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022
From
LianBio
Via
GlobeNewswire
Tickers
LIAN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.